Pleiotropic effects of selective CDK inhibitors on human normal and cancer cells

Biochemical Pharmacology

Volumn 76, Issue 11, 2008, Pages 1503-1514

  Wesierska Gadek, Józefa ^a   Hajek, Susanne B ^a   Sarg, Bettina ^b   Wandl, Stefanie ^a   Walzi, Eva ^a   Lindner, Herbert ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

CDK inhibitors; Cell cycle arrest; CLIMP 63; E6 oncoprotein; HPV18; p53 Tumor suppressor

Indexed keywords

CASPASE 3; CELL MEMBRANE PROTEIN; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 7; CYCLIN DEPENDENT KINASE 9; CYCLIN DEPENDENT KINASE INHIBITOR; CYTOSKELETON LINKING MEMBRANE PROTEIN 63; OLOMOUCINE; PROTEIN E6; PROTEIN P53; ROSCOVITINE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG SELECTIVITY; ELECTROPHORESIS; ENZYME INHIBITION; FIBROBLAST; FLOW CYTOMETRY; HELA CELL; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNOBLOTTING; MASS SPECTROMETRY; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

CELL CYCLE; CELL LINE; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASES; HUMANS; KINETIN; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PURINES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 55949135472     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2008.07.040     Document Type: Article

References (55)

1. Norbury C., and Nurse P. Animal cell cycles and their control. Annu Rev Biochem 61 (1992) 441-470
2. van den Heuvel S., and Harlow E. Distinct roles for cyclin-dependent kinases in cell cycle control. Science 262 (1993) 2050-2054
3. Morgan D.O. Principles of CDK regulation. Nature 374 (1995) 131-134
4. Weinberg R.A. The molecular basis of carcinogenesis: understanding the cell cycle clock. Cytokines Mol Ther 2 (1996) 105-110
5. Santamaria D., and Ortega S. Cyclins and CDKs in development of cancer. Lessons from genetically modified mice. Front Biosci 11 (2006) 1164-1188
6. Malumbres M., and Barbacid M. Cell cycle kinases in cancer. Curr Opin Genet Dev 17 (2007) 60-65
7. Senderowicz A.M. Small-molecule cyclin-dependent kinase modulators. Oncogene 22 (2003) 6609-6620
8. Sherr C.J., and Roberts J.M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13 (1999) 1501-1512
9. de Carcer G., de Castro I.P., and Malumbres M. Targeting cell cycle kinases for cancer therapy. Curr Med Chem 14 (2007) 969-985
10. Lane D.P., and Fischer P.M. Turning the key on p53. Nature 427 (2004) 789-790
11. Wesierska-Gadek J., Schloffer D., Kotala V., and Horky M. Escape of p53 protein from E6-mediated degradation in HeLa cells after cisplatin therapy. Int J Cancer 101 (2002) 128-136
12. Vesely J., Havlicek L., Strnad M., Blow J.J., Donella-Deana A., Pinna L., et al. Inhibition of cyclin-dependent kinases by purine analogues. Eur J Biochem 224 (1994) 771-786
13. Meijer L., Borgne A., Mulner O., Chong J.P., Blow J.J., Inagaki N., et al. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem 243 (1997) 527-536
14. De Azevedo W.F., Leclerc S., Meijer L., Havlicek L., Strnad M., and Kim S.H. Inhibition of cyclin dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. Eur J Biochem 243 (1997) 518-526
15. Gray N., Detivaud L., Doerig C., and Meijer L. ATP-site directed inhibitors of cyclin-dependent kinases. Curr Med Chem 6 (1999) 859-875
16. Knockaert M., Greengard P., and Meijer L. Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharm Sci 23 (2002) 417-425
17. Fischer P.M., and Gianella-Borradori A. Recent progress in the discovery and development of cyclin-dependent kinase inhibitors. Expert Opin Investig Drugs 14 (2005) 457-477
18. Blagosklonny M.V., Demidenko Z.N., and Fojo T. Inhibition of transcription results in accumulation of Wt p53 followed by delayed outburst of p53-inducible proteins: p53 as a sensor of transcriptional integrity. Cell Cycle 1 (2002) 67-74
19. Wesierska-Gadek J., and Schmid G. Dual action of the inhibitors of cyclin-dependent kinases: targeting of the cell cycle progression and activation of wild-type p53 protein. Expert Opin Investig Drugs 14 (2005) 457-477
20. Wesierska-Gadek J., Gueorguieva M., Kramer M.P., Ranftler C., Sarg B., and Lindner H. A new, unexpected action of olomoucine, a CDK inhibitor, on normal human cells: up-regulation of CLIMP-63, a cytoskeleton-linking membrane protein. J Cell Biochem 102 (2007) 1405-1419
21. Wojciechowski J., Horky M., Gueorguieva M., and Wesierska-Gadek J. Rapid onset of nucleolar disintegration preceding cell cycle arrest in roscovitine-induced apoptosis of human MCF-7 breast cancer cells. Int J Cancer 106 (2003) 486-495
22. Ljungman M., and Paulsen M.T. The cyclin-dependent kinase inhibitor roscovitine inhibits RNA synthesis and triggers nuclear accumulation of p53 that is unmodified at Ser15 and Lys382. Mol Pharmacol 60 (2001) 785-789
23. Janicke R.U., Sprengart M.L., Wati M.R., and Porter A.G. Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem 273 (1998) 9357-9360
24. Devarajan E., Sahin A.A., Chen J.S., Krishnamurthy R.R., Aggarwal N., Brun A.M., et al. Down-regulation of caspase 3 in breast cancer: a possible mechanism for chemoresistance. Oncogene 21 (2002) 8843-8851
25. Wesierska-Gadek J., Gueorguieva M., and Horky M. Dual action of cyclin-dependent kinase inhibitors: induction of cell cycle arrest and apoptosis. A comparison of the effects exerted by roscovitine and cisplatin. Pol J Pharm 55 (2003) 895-902
26. Wesierska-Gadek J., Gueorguieva M., and Horky M. Roscovitine-induced up-regulation of p53AIP1 protein precedes the onset of apoptosis in human MCF-7 breast cancer cells. Mol Cancer Ther 4 (2005) 113-124
27. Oda K., Arakawa H., Tanaka T., Matsuda K., Tanikawa C., Mori T., et al. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 102 (2000) 849-862
28. Wesierska-Gadek J., Schmitz M.L., and Ranftler C. Roscovitine-activated HIP2 kinase induces phosphorylation of wt p53 at Ser-46 in human MCF-7 breast cancer cells. J Cell Biochem 100 (2007) 865-874
29. Schang L.M., Coccaro E., and Lacasse J.J. Cdk inhibitory nucleoside analogs prevent transcription from viral genomes. Nucleosides Nucleotides Nucleic Acids 24 (2005) 829-837
30. Schang L.M. Discovery of the antiviral activities of pharmacologic cyclin-dependent kinase inhibitors: from basic to applied science. Expert Rev Anti-infective Ther 3 (2005) 145-149
31. Schweizer A., Ericsson M., Bachi T., Griffiths G., and Hauri H.P. Characterization of a novel 63 kDa membrane protein. Implications for the organization of the ER-to-Golgi pathway. J Cell Sci 104 (1993) 671-683
32. 2 cell cycle arrest. Cancer Res 64 (2004) 4487-4497
33. Wesierska-Gadek J., Gueorguieva M., and Wojciechowski-Trajkovska S. In vivo activated caspase-3 cleaves PARP-1 in rat liver after administration of the hepatocarcinogen N-nitrosomorpholine (NNM) generating the 85 kDa fragment. J Cell Biochem 93 4 (2004) 774-787
34. Wesierska-Gadek J., Gueorguieva M., Ranftler C., and Zerza-Schnitzhofer G. A new multiplex assay allowing simultaneous detection of the inhibition of cell proliferation and induction of cell death. J Cell Biochem 96 1 (2005) 1-7
35. 1 checkpoint. J Cell Biochem 80 (2000) 85-103
36. Vindelov L.L., Christensen I.J., and Nissen N.J. A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry 3 (1983) 323-327
37. Wesierska-Gadek J, Wandl S, Kramer MP, Pickem C, Krystof V, Hajek SB. Roscovitine up-regulates p53 protein and induces apoptosis in human HeLaS3 cervix carcinoma cells. J Cell Biochem 2008 DOI 10.1002/jcb.21903.
38. Murray A.W., and Marks D. Can sequencing shed light on cell cycling?. Nature 409 (2001) 844-846
39. Fisher R.P. Secrets of a double agent: CDK7 in cell-cycle control and transcription. J Cell Sci 118 (2005) 5171-5180
40. Palancade B., and Bensaude O. Investigating RNA polymerase II carboxyl-terminal domain (CTD) phosphorylation. Eur J Biochem 270 (2003) 3859-3870
41. Meinhart A., Kamenski T., Hoeppner S., Baumli S., and Cramer P. A structural perspective of CTD function. Genes Dev 19 (2005) 1401-1415
42. Marshall R.M., and Grana X. Mechanisms controlling CDK9 activity. Front Biosci 11 (2006) 2598-2613
43. Scheffner M., Huibregtse J.M., Vierstra R.D., and Howley P.M. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75 (1993) 495-505
44. Scheffner M., Werness B.A., Huibregtse J.M., Levine A.J., and Howley P.M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63 (1990) 1129-1136
45. Goodwin E.C., and DiMaio D. Repression of human papillomavirus oncogenes in HeLa cervical carcinoma cells causes the orderly reactivation of dormant tumor suppressor pathways. Proc Natl Acad Sci 97 (2000) 12513-12518
46. Wang W., and Deiry WS El. Restoration of p53 to limit tumor growth. Curr Opin Oncol 20 (2008) 90-96
47. Schweizer A., Rohrer J., Slot J.W., Geuze H.J., and Kornfeld S. Reassessment of the subcellular localization of p63. J Cell Sci 108 Pt 6 (1995) 2477-2485
48. Vedrenne C., Klopfenstein D.R., and Hauri H.P. Phosphorylation controls CLIMP-63-mediated anchoring of the endoplasmic reticulum to microtubules. Mol Biol Cell 16 4 (2005) 1928-1937
49. Klopfenstein D.R., Klumperman J., Lustig A., Kammerer R.A., Oorschot V., and Hauri H.P. Subdomain-specific localization of CLIMP-63 (p63) in the endoplasmic reticulum is mediated by its luminal alpha-helical segment. J Cell Biol 153 6 (2001) 1287-1300
50. Razzaq T.M., Bass R., Vines D.J., Werner F., Whawell S.A., and Ellis V. Functional regulation of tissue plasminogen activator on the surface of vascular smooth muscle cells by the type-II transmembrane protein p63 (CKAP4). J Biol Chem 278 43 (2003) 42679-42685
51. Conrads T.P., Tocci G.M., Hood B.L., Zhang C.O., Guo L., Koch K.R., et al. CKAP4/p63 is a receptor for the frizzled-8 protein-related antiproliferative factor from interstitial cystitis patients. J Biol Chem 281 (2006) 37836-37843
52. Pignolo R.J., Rotenberg M.O., Horton J.H., and Cristofalo V.J. Senescent WI-38 fibroblasts overexpress LPC-1, a putative transmembrane shock protein. Exp Cell Res 240 2 (1998) 305-311
53. Nikonov A.V., Hauri H.P., Lauring B., and Kreibich G. Climp-63-mediated binding of microtubules to the ER affects the lateral mobility of translocon complexes. J Cell Sci 120 Pt 13 (2007) 2248-2258
54. Wall N.R., O'Connor D.S., Plescia J., Pommier Y., and Altieri D.C. Suppression of survivin phosphorylation on Thr34 by flavopiridol enhances tumor cell apoptosis. Cancer Res 63 1 (2003) 230-235
55. Nikonov A.V., and Kreibich G. Organization of translocon complexes in ER. Biochem Soc Trans 31 Pt 6 (2003) 1253-1256